Johnson & Johnson’s TB drug SIRTURO receives full approval from FDA and EC
In a significant development for the treatment of drug-resistant tuberculosis (TB), Johnson & Johnson has announced that SIRTURO (bedaquiline) has received full approval from the U.S. Food and Drug Administration (FDA) and the European Commission (EC). This approval marks a pivotal milestone in the fight against pulmonary TB that is resistant to standard treatments like […]